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pharmaceutical expenditure for patients with hypertension. RESULTS: Pharma-
ceutical expenditures increased with age and the duration of hypertension. A
mixed effect model indicated that being widowed or separated significantly in-
creased pharmaceutical expenditures by $219.12 (P0.0001) and $206.84 (P0.0001)
respectively; the pharmaceutical expenditures decreases by $2.79 (P0.01) if BMI
decreased by 1 kg/m2 from survey round 3 to round 5. Pharmaceutical expenditures
decreased with family size and education level. Compared with the uninsured,
those with public insurance spent $208.33 (P0.0001) more, and those with private
insurance spent $121.01 (P0.0001)more on prescribed medicine for essential
hypertension. CONCLUSIONS: Age, duration of hypertension, marriage status,
BMI, type of insurance, and education were found as significant determinants of
pharmaceutical expenditures for patients with hypertension.
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OBJECTIVES: To investigate the association between blood pressure (BP) control
and healthcare utilization and costs in newly treated patientswith hypertension in
a managed care organization. METHODS: Patients who met the selection criteria
were identified from a healthcare organization during July 2005 – May 2008: 1) age
18; 2) 1 diagnosis of hypertension; 3) 1 prescription for hypertension; 4) con-
tinuously eligible with the organization 6 months before and 12 months after the
initiation of the antihypertensive agent(s) (index date); and 5) 2 blood pressure
(BP) readings with 1 at the index date, and another measured over 90 days of
receivingmedications. Patientswere classified into BP at goal vsersus BP not at goal
by the mean BP during 90 to 365 days after the index date. BP goal is defined as
140/90mmHg for hypertensive patientswithout diabetes, and130/80mmHg for
hypertensive patients with diabetes. Health care utilization and costs for the 12-
month post index date were compared between groups. RESULTS: We identified
1056 patients, themean age was 63 years old, and 54%were females. Overall, there
were 61% of the patients with BP at goal and 36% of the patients with comorbid
hypertension and diabetes met BP goal. The patients who met BP goal had higher
number of outpatient visits (19.0 vs. 14.0; p0.001), higher prescription fills (31.0 vs.
25.0; p0.001), and higher total costs ($7016 vs. $4628; p0.001) than those not at
goal. CONCLUSIONS: To achieve BP goal, physicians would have to follow-up with
patients frequently and emphasize the benefits ofmaintaining BP to goal. Although
the economic benefits of BP control is not immediately seen in the first year treat-
ment in this study, other studies have shown that long term control does prevent
the complications of hypertension, and demonstrate the long term economic ben-
efits. Additional research is warranted.
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OBJECTIVES: To analyze the structure of expenses associated with warfarin dose
adjustment and consequent international normalized ratio (INR) monitoring for
effective stroke prevention in patients with atrial fibrillation.METHODS: The pres-
ent study was designed as cost of illness analysis. Expenses associated with INR
monitoring and warfarin dose adjustment were calculated for four different cir-
cumstances: 1) for obligatorymedical insurance system according the current gen-
eral tariff agreement; 2) for patients managed in outpatient department of Univer-
sity hospital using prices for consultations and coagulation tests; 3) for those
controlling INR in commercial laboratory using their price list; and 4) for self-
monitored patients using costs for coagulomether and test strips purchasing.
RESULTS:Within the obligatory medical insurance system total expenses for war-
farin management accounted for 4058 Roubles/person per year, but share of ex-
penses for warfarin purchasingwas less than 1%; for patients treated in outpatient
department of University clinic that estimated for 13019 Roubles/person per year
and 0.03%; in the case of INR control in commercial laboratory – 18648 Roubles/
person per year and 0.02%; and for self-moniroring – from 40,405 Roubles/person
per year (0.01%) in the first year (that includes the fee for coagulomether purchas-
ing) to 7405 Roubles/person per year (0.05%) in consequent years respectively.
CONCLUSIONS: Regardless the strategy of INR control, concomitant expenses as-
sociated with warfarin dose adjustment and subsequent efficiency and safety
monitoring is more than 100-fold higher than the price of warfarin itself.
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OBJECTIVES:One of themajor complications aftermajor orthopedic surgery (OS) is
Venous Thromboembolism (VTE). VTE is an important condition not only because
of the potential long term complications to patients, but also the cost burden it
brings to the society. Unfortunately, no data readily exists showing the cost of VTE
prophylaxis (VTEp) in Turkey. Therefore, this study calculates the diagnosis and
treatment costs of VTEp aftermajor OS based on expert opinion.METHODS:Health
Economists of BayerTürk created a survey to a)determine the resources utilized in
diagnosis and treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism
(PE), b)establish the costs corresponding to potential complications of VTEp; intra
cerebral hemorrhages (ICH) and gastrointestinal bleeds (GIB) The survey was com-
pleted by the pioneers in Orthopedics and Traumatology, cardiovascular diseases,
hematology, gastroenterology, neurology and pulmonary diseases, based on daily
clinical practice and guidelines. An Expert Panel preceded the completion of sur-
veys, during which a consensus is reached. Based on the consensus, the costs of
VTEp are calculated from payer’s perspective. RESULTS: According to expert opin-
ion, there are approximately 20,000-30,000 TKR, 25,000-30,000 THR surgeries are
performed annually in Turkey. The major bleeding rates among these patients is
approximately 1%, half of them being ICH and the other half being GIB. Ddiagnosis
and treatment costs of VTEp and major bleeds calculated based on expert opinion
are: a)Diagnosis cost of DVT (PE): TL 33 (48) for inpatients and TL 126 (150) for
outpatients, b)Treatment cost of DVT (PE): TL 372 (1177) if hospitalization is re-
quired and TL 162 (757) if not, c)Diagnosis cost of ICH (GIB): TL 81 (192), d)Treatment
cost of ICH (GIB): TL 682 (537). CONCLUSIONS: This study displays the importance
of VTE prophylaxis. Diagnosis and treatment of VTE creates disease and cost bur-
den to the public and the society.
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OBJECTIVES:Orthopedic surgery presents a high risk of venous thromboembolism
(VTE). Without prophylaxis, between 41% and 85% of patients who undergo high-
risk orthopedic procedures develop deep vein thrombosis (DVT) and up to 10%
develop pulmonary embolism (PE). Furthermore, the economic burden of VTE is
perceived as substantially high in Colombia. Few data on the total economic bur-
den of DVT and PE associated to orthopedic surgery, however, is available in the
country. The objective of this study was to quantify the economic burden of DVT
and PE in the Colombian health care setting.METHODS:Delphi Panelmethodology
was used to estimate 2011 resource utilization associated with VTE treatment
events in patients undergoing hip and knee replacement. Delphi Panel contained
specialists from the private Colombian setting. Local available databases and pub-
lished literature was retrieved. Cost estimations (inpatient and outpatient costs,
acquisition costs, bleedings costs, intracranial hemorrhages and other associated
costs) considered the private perspective, using unit cost data from Seguro Obliga-
torio de Accidentes de Tránsito (SOAT). RESULTS: In Colombia the cost of hip
replacement surgery (in 2011USD)was estimated at USD $3182 and the cost of knee
replacement at USD$2942. Mean symptomatic PE costs for inpatients with hip
replacement was USD$6651 and DVT mean costs was USD$4061. Cost of treating
minor bleeding adverse events in patients with hip replacement, was estimated as
USD$4157 andmajor bleeding as USD$6171. Themean symptomatic PE costs (2011
US$) for inpatients with knee replacement was USD$6538 and DVTwas USD $3801.
Cost of treating minor bleeding adverse events in patients with knee replacement,
was estimated as USD$3931 andmajor bleeding as USD$5945. CONCLUSIONS: The
occurrence of VTE events related to orthopedic surgery can significantly impact
overall costs of orthopedic surgery in Colombia.
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OBJECTIVES: Deep vein thrombosis (DVT) and pulmonary embolism (PE) are clini-
cal manifestations of VTE that can occur with or without symptoms. A major risk
factor for VTE is orthopedic surgery. The economic burden of recurrent VTE asso-
ciated to hip and knee replacement is perceived as considerable high within the
Argentinean health care system; however, the data supporting this perception is
scarce. The objective of this study is to document the health care resource utiliza-
tion and costs associatedwith the care of VTEp and its complications related to hip
and knee replacement in Argentina. METHODS: Data regarding health care re-
sources associated with the treatment of VTE and major and minor bleeding was
estimated using Delphi panel methodology in 2011 (specialists from public and
private settings); locally available databases and published literature. Costs esti-
mations (inpatient and outpatient costs, acquisition costs, bleedings costs, intra-
cranial hemorrhages and other associated costs) considered a weighted average of
three different perspectives: 1) private; 2) public health care system; and 3) social
insurance. Costs are reported in 2011 USD. RESULTS: The estimated mean cost -if
events occur while hip replacement inpatient surgery- of treating symptomatic PE
is approximately USD$4510while the cost of DVTwas estimated inUSD $2904. Cost
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of treating minor bleeding adverse events related to VTEp was estimated as
USD$2679 and major bleeding was USD$5564. Similar estimations were found for
knee replacement events. CONCLUSIONS: The occurrence of VTE events related to
orthopedic surgery can significantly impact the costs of surgery, particularly given
that in Argentina the cost of hip replacement was estimated as USD $1959 and the
cost of knee replacement as USD $1193. One must therefore consider treatments
given for VTE prevention, as these therapies not only impact survival and quality of
life but can also substantially impact the efficient use of health care resources.
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OBJECTIVES:To evaluate the healthcare cost for themanagement of diabetes along
with other co-morbidities condition.METHODS: A cross-sectional study was con-
ducted in the Community setup of Warangal, India for a period of three months.
Only the educated Diabetic patients with other comorbidities were enrolled in the
study. The data collected were cost of medications, lab tests, consultation fee,
transportation cost. The average total healthcare cost was calculated based on the
previous two months expenses of each patient. RESULTS: A total of 100 patients
were evaluated in the study period. Out of 100 patients, majorities were in the age
group of 41-61 yrs 66 (66%) and also found to be higher in men 63 (63%) than in
women 37 (37%). Most of the patients were diabetes with hypertension, dyslipide-
mia. The average cost of medications per patient Rs. 1540 (72.81%), the average
laboratory cost per patient Rs. 350 (16.55%), the average doctors consultation fee
per patient Rs.175 (8.27%), the average transportation charges per patient Rs.50
(2.36%). The most common drugs prescribed in the study were Metformin, Gliben-
clamide, Gliclazide, Insulin, Ramipril, Amlodipine, Telmisartan, Metoprolol, Hy-
drochlorothiazide, Furosemide, Atorvastatin and Aspirin. The most common lab-
oratory test includes FBS/PPBS/RBS/HbA1C, lipid profiles, urine analysis, Hb,
Electrolytes and Sr.Creatinine. The average total healthcare cost for two months
was found to be Rs.2115 per patient. CONCLUSIONS: In summary, this is the first
Indian healthcare cost study conducted in the community setup. Diabetes imposes
an enormous economic burden on the healthcare system worldwide. This burden
will continue to increase in the next two decades. More prevention efforts and
resources are required to reduce this burden and to provide basic diabetes care in
the low- and middle-income countries.
PCV46
ASSESSING THE COST-EFFECTIVENESS OF THE RECOMMENDED
ANTIHYPERTENSIVE DRUG CLASSES IN FRANCE USING A LIFETIME MARKOV
MODEL
Gerlier L1, Midy F2, Lièvre M3, Cohn E2, Vellopoulou K1, Maurel F4, Lamotte M1
1IMS Health Consulting Group, Vilvoorde, Belgium, 2Haute Autorité de Santé, Saint-Denis La
Plaine, France, 3Université Claude Bernard, Lyon, France, 4IMS Health Consulting Group,
Puteaux, France
OBJECTIVES: The management of arterial hypertension in France starts with an
evaluation of the patient’s cardiovascular risk (function of age, sex, cholesterol
level, systolic blood pressure [SBP]) and if necessary, the prescription of a recom-
mended class among angiotensin converting enzyme (ACE)-inhibitors, angiotensin
receptor blockers (ARBs), beta-blockers, calcium channel blockers (CCB) and thia-
zide diuretics. The objective of this study was to assess, for different patient’s
profiles, the cost-effectiveness of the recommended antihypertensive classes in
France. METHODS: A cohort of newly treated patients entered a Markov model,
using 1-month cycles in the first year, 1-year cycles until 10 years then lifetime
extrapolation of costs and benefits. The cohort was characterized by its cardiovas-
cular risk, evaluated via the France-specific Framingham equation. The risk reduc-
tions per class versus placebowere taken from themost recentmeta-analyses. The
probability to switch from monotherapy to bitherapy and tritherapy was depend-
ing on the achieved SBP (target 140mmHg) and the class-specific persistence. Na-
tional health care databases provided persistence and costs data. Discount rate
was 4% (costs and life-years). RESULTS: In low-risk patients (65-year-old female,
SBP 150mmHg), incremental cost-effectiveness vs. placebo ranged from 101€/life-
year gained (ACE-inhibitors followed by ACE-inhibitors/thiazides) to 7,722€/life-
year gained (beta-blockers followed by beta-blockers/CCB). Savings and extra ben-
efits vs. placebo were obtained in high-risk patients (74-year-old diabetic male,
smokers, SBP 180mmHg): up to 0.57 life-years gained with total costs reduced from
17,630€ to 15,403€ (ACE-inhibitors followed by ACE-inhibitors/CCB, least expensive
sequence) and 15,953€ (beta-blockers followed by beta-blockers/ARBs,most expen-
sive sequence). The classes rankingwas influenced by the persistence and diabetes
incidence. The differenceswere significant vs. placebo but not between the classes,
as per probabilistic sensitivity analysis. CONCLUSIONS: This lifetime model sug-
gests that all recommended anti-hypertensive drugs in France are very cost-effec-
tive versus placebo, and, in higher-risk patients, are even cost-saving with savings
comparable among the classes.
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OBJECTIVES: Pulmonary arterial hypertension (PAH) is a chronic disease charac-
terized by progressive elevation of pulmonary artery pressure and vascular resis-
tance, leading to right-sided heart failure and premature death. The objective
of the present research was to assess the clinical and economic aspects of current
oral treatments options for PAH, New York Heart Association (NYHA) functional
classes II and III, from the Brazilian Public Health Systemperspective.METHODS:A
literature review was conducted on the efficacy and safety of ambrisentan, bosen-
tan and sildenafil in patients diagnosed with PAH, in order to support the assump-
tion of clinical equivalence between the treatments and the development of a
cost-minimization analysis. The clinical outcome of interest was improvement in
the distance (in meters) walked in 6 minutes (6MWD). For the economic analysis,
direct medical costs were considered. Treatment, diagnostic, and procedure costs
were obtained from public price/reimbursement databases. Government acquisi-
tion prices were used for all drugs. Costs associated with adverse drug reactions
and treatment withdrawals were also considered. A one-year time-horizon was
used and all costs were presented in 2011 Brazilian currency (1BRL0.60USD).
RESULTS: There were no studies directly comparing any of the targeted agents.
Thus, an indirect comparison of placebo controlled trials of selected PAH therapies
was conducted. Standardized mean differences (SMD) between agents (over pla-
cebo) was calculated and the magnitude of effects between the comparators sug-
gested similar clinical efficacy over 12–16 weeks of treatment. Confidence intervals
of treatment effects overlapped substantially and supported the clinical assump-
tion. The total annual/monthly costs for the interventions were R$13,169.76/
R$1,097.48 for ambrisentan, R$13,226.86/R$1,102.24 for sildenafil, and R$30,227.70/
R$2,518.98 for bosentan. CONCLUSIONS: Ambrisentan was identified as the
alternativewith the lowest cost and similar clinical outcomes comparedwith other
selected therapies for treating patients diagnosed with PAH, NYHA functional
classes II and III, under the Brazilian public perspective.
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OBJECTIVES: To compare costs and effectiveness of dabigatran etexilate (DAB)
versus acetylsalicilic acid (ASA) in patients with Non-Valvular Atrial Fibrillation
(NVAF) from a private and public health care system perspective in Brazil.
METHODS: AMarkov model was built to compare DAB versus ASA to derive incre-
mental cost effectiveness ratio (ICER) of DAB based on a mixed treatment compar-
ison and a modified Delphi panel with Brazilian experts (local clinical practice
pattern on themanagement ofNVAFpatients). Themodel estimated the number of
ischaemic and haemorrhagic strokes, systemic embolisms, intracranial hemor-
rhages, transient ischaemic attacks, extracranial hemorrhages, minor bleeds and
acute myocardial infarctions associated with the respective treatments. To each
clinical event costs, disabilities and/or reduction in quality of life, and risk of death
were assigned. Only directmedical costs were considered and a discount rate of 5%
was assumed, according to Brazilian HTA guidelines. A probabilistic sensitivity
analysis was designed to assess uncertainty. RESULTS:Under both, the private and
public perspective, DAB was associated with additional 0.31 life years gained (LY),
additional 0.60 QALYs and demonstrated a lower incidence of intracranial events
versus ASP, resulting in a lower event costs (-R$ 1,057.84 and - R$ 3,006.07) and
follow up costs. The ICER for DAB versus ASAwas R$ 38,511.06/LY and R$ 31,379.80/
QALY from the public perspective and DAB was dominant from the private per-
spective. Sensitivity analyses confirmed the cost-effectiveness of DAB.
CONCLUSIONS: Findings suggest that DAB can be cost-effective for stroke preven-
tion when used instead of ASA in NVAF patients in Brazil, given that DAB was
dominant in the private sector and ICERS were below the threshold of other tech-
nologies reimbursed in the public health care sector.
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OBJECTIVES: Although medication advice is a key component in cardiac rehabili-
tation (CR) program, little is known about its effectiveness on patient medication
use behaviors. This project aimed to assess the cost-effectiveness of CR programon
patient adherence to cardiac medication and the number of hospitalization
avoided. METHODS: Using MarketScan® Medicaid database, patients with acute
myocardial infarction (AMI) were targeted. By using propensity scores, 471 patients
receiving CR programs during 2003- 2007were 1:1matchedwith 471 controls (with-
out CR) on patient demographics, comorbidities and healthcare costs before the CR
started. The economic perspective was that of third-payer sector so only direct
medical costs were included (costs attributed to CR program and the use of cardiac
specific medical services and medications). Main outcomes were patient adher-
ence to cardiacmedicationmeasured byMedication Possession Ratio and the num-
ber of cardiac related hospitalization. The cardiac medications studied were 1
selective-blockers, angiotensin converting enzyme inhibitors and angiotensin re-
ceptor blockers. The outcomes were estimated every 4 months during 1-year fol-
low-up. Cost-effectiveness of CR programwas determined by the incremental cost-
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